prostate pathophysiology charles l. hitchcock, md phd associate professor - clinical department of...
TRANSCRIPT
![Page 1: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/1.jpg)
Prostate Pathophysiology
Charles L. Hitchcock, MD PhD
Associate Professor - Clinical Department of Pathology
![Page 2: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/2.jpg)
Learning Objectives
• Primary Objective:• Discuss benign and cancerous growth of the prostate
gland.
• Secondary Objectives: • Discuss screening and diagnosis of prostatic tumors. • Describe clinical and histological features of benign
prostatic hyperplasia (BPH) and prostate cancers, their identification and treatments.
• Identify issues related to prostate cancer screening and modifiable behaviors that impact its development
![Page 3: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/3.jpg)
Objective 1
• Discuss screening and diagnosis of prostatic tumors.
![Page 4: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/4.jpg)
Prostatic Zones
• B: bladder• U: prostatic urethra• SV: seminal vesicle• 1: Peripheral zone
• 65% glands• 2: Central zone
• 30% glands• 3: Transitional zone
• 5% of glands• 4: Anterior fibromuscular zone
![Page 5: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/5.jpg)
Nonglandular Tissue
• Capsule• Sphincters• Fibromuscular tissue
![Page 6: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/6.jpg)
Digital Rectal Exam DRE For Detecting Prostate Cancer
![Page 7: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/7.jpg)
Benign Nodular Hyperplasia
![Page 8: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/8.jpg)
Transrectal US + Biopsy
![Page 9: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/9.jpg)
Screening For Prostate Cancer
![Page 10: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/10.jpg)
Prostate Specific Antigen PSA
• PSA is a 33 kDa serine protease • Normally produced by prostatic glandular
epithelium. • Functions in liquefaction of the seminal
coagulum
![Page 11: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/11.jpg)
What does a PSA Value Mean
• A PSA value between 4 ng/ml and 10 ng/ml do not distinguish between a benign and a neoplastic process, but does indicate a 20-25% risk for prostate cancer.
• The most common benign processes include: glandular hyperplasia, prostatitis, trauma, and DRE.
• The risk of prostate cancer >50% for PSA values > 10 ng/mL, and then increases as the PSA level rises.
![Page 12: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/12.jpg)
Key Points
• Transition zone around the urethra – most common site of BPH.
• Peripheral zone = most common site of cancers
• DRE - poor screen for cancer
• Cystoscopy good for BPH diagnosis
![Page 13: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/13.jpg)
Key Points
• Elevated PSA is not diagnostic of cancer.
• PSA and DRE should be used together for screening.
• Cannot distinguish between a clinically indolent and aggressive carcinoma.
• Leads to increased biopsies and risk of infection and bleeding.
• PSA should not be performed without a patient’s informed consent.
![Page 14: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/14.jpg)
Objective 2
• Describe clinical and histological features of benign prostatic hyperplasia (BPH) and prostate cancers, their identification and treatments.
![Page 15: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/15.jpg)
Clinical Presentations of Prostate Tumors – Early Onset
• Frequency• Urgency• Hesitancy• Incomplete emptying• Straining• Decrease force• Dribbling• Nocturia• Hematuria
Benign Prostatic Hyperplasia
Prostate Cancer
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
Yes Yes
No Yes
![Page 16: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/16.jpg)
Clinical Features of Prostatic Tumors
• Late onset BPH• Bladder diverticula
• Hydronephrosis
• Pyelonephritis
• Late onset prostatic cancer• Metastatic disease
• Bone pain – low back
• Weight loss
![Page 17: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/17.jpg)
Key Points
• Clinical presentation of BPH and prostatic cancer may be identical when early.
• Normal glandular tissue has two cell layers• Fibromuscular stroma propel secretions out
of the gland.
![Page 18: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/18.jpg)
Glandular Tissue
• Ducts and acini have a similar caliber and appearance.
• Columnar secretory epithelial cells
• Underlying basal cells• Basement membrane
NeuroendocrineCell
![Page 19: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/19.jpg)
Normal Prostate
Fibromuscular Stroma
Gland
GlandGland
Fibromuscular Stroma
![Page 20: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/20.jpg)
Normal ProstateFibromuscular
Stroma
Secretory Cells
BasalCells
![Page 21: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/21.jpg)
Benign Prostatic Hyperplasia
Normal Prostate Hyperplasia Nodules
Urethra Urethra
![Page 22: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/22.jpg)
Benign Prostatic Hyperplasia
![Page 23: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/23.jpg)
Benign Prostatic Hyperplasia
Fibromuscular HyperplasiaGlandular Hyperplasia
![Page 24: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/24.jpg)
Dihydrotestosterone and BPH
![Page 25: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/25.jpg)
Treatment of BPH
![Page 26: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/26.jpg)
Treatment of BPH
Laser PVP
TURP
![Page 27: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/27.jpg)
Prostate Carcinoma
![Page 28: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/28.jpg)
Prostate CarcinomaCapsular Invasion
Perineural Invasion Lymphatic Invasion
![Page 29: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/29.jpg)
Adenocarcinoma
![Page 30: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/30.jpg)
Score 1-2 – 10x Score 5 – 10x
Gleason Grading
![Page 31: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/31.jpg)
Prostatic Carcinoma TNM Staging
![Page 32: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/32.jpg)
Prostatic Carcinoma Treatment
• Watchful waiting or active surveillance
• Surgery: • Lymphadenectomy
• Radical prostatectomy, cryosurgery
• TURP
• Complications: impotence, shortening of the penis, incontinence of urine and/or stool, inguinal hernia
• Radiation - external & internal• Complications: impotence, incontinence, and increased risk
for bladder and rectal cancers
![Page 33: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/33.jpg)
Prostatic Carcinoma Treatment
• Hormonal
• Orchiectomy
• Estrogen
• GnRH analogs (leuprolide) - suppresses LH-RH synthesis
• Antiandrogens (flutamide) - inhibits androgen uptake & nuclear binding
• Adrenal androgen synthesis blockade (ketoconazole)
• Complication: hot flashes, impaired sexual function , osteoporosis, diarrhea, pruritus
• Chemotherapy
• Immunotherapy
![Page 34: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/34.jpg)
Prostatic Carcinoma Treatment
• Radiation - external & internal
• Complications: impotence, incontinence, and increased risk for bladder and rectal cancers
• Hormonal
• Orchiectomy
• Estrogen
• GnRH analogs (leuprolide) - suppresses LH-RH synthesis
• Antiandrogens (flutamide) - inhibits androgen uptake & nuclear binding
• Adrenal androgen synthesis blockade (ketoconazole)
• Complication: hot flashes, impaired sexual function , osteoporosis, diarrhea, pruritus
• Chemotherapy
• Immunotherapy
![Page 35: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/35.jpg)
Key Points
• Clinical presentation of BPH and prostatic cancer may be identical with early onset.
• Normal glandular tissue has two cell layers.
• Fibromuscular stroma propels secretions out of the gland.
• The incidence of BPH increases with age.• Glandular and stromal hyperplasia
commonly occurs in the transitional zone.
• TX: Watchful waiting, hormonal blockade, surgery
![Page 36: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/36.jpg)
Key Points – 2 Prostate Cancer
• Often multifocal – separate tumors• Adenocarcinomas• Gleason grading system• TNM Staging – incidental (I) to metastatic (IV)• Six methods of treatment
![Page 37: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/37.jpg)
Objective 3
• Identify issues related to prostate cancer screening and modifiable behaviors that impact its development.
![Page 38: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/38.jpg)
Risk Factors – Nodular Prostatic Hyperplasia
• Age – incidence increases with age, with 70% of men over 60 having it.
• Family history – does increase the risk• Obesity• High BP• Low HDL• Diabetes• Peripheral vascular disease• Poor diet and lack of exercise
Heart DiseaseRisk Factors
![Page 39: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/39.jpg)
Risk Factors – Prostate Cancer
• Gender• Most common malignancy in U.S. men• >217,000 new cases in 2013 (25% of new cancers in men)• 2nd leading cause of death among men• >32,000 deaths in 2013. • ~1/6 lifetime death risk• mortality African-American men is 2x > Caucasian men• Incidence increased in 1988-92 but has declined in 1992-95,
and has leveled off since 1995
![Page 40: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/40.jpg)
Risk Factors – Prostate Cancer
• Age• Incidence of latent carcinoma is:
• 20% in men 50-59• ~70% in 70-80
• 64% of all prostate cancers are diagnosed in men > 65 years
• Ethnicity and Race• incidence in AA 1.5 - 2x > Caucasian men
• U.S. >> Asia and South America• High fat diet - ?
![Page 41: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/41.jpg)
Risk Factors – Prostate Cancer
• Hereditary form in ~ 10% of all cases and up to 40 percent of early onset disease.
• Family history of prostate carcinoma• Hereditary prostate cancer gene 1, or HPC1, linked
in prostate cancer families to the RNASEL gene.
![Page 42: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/42.jpg)
Prostate Screening
![Page 43: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/43.jpg)
PSA – Key Points
• “The PSA test measures the blood level of PSA, a protein that is produced by the prostate gland. The higher a man’s PSA level, the more likely it is that he has prostate cancer. However, there are additional reasons for having an elevated PSA level, and some men who have prostate cancer do not have elevated PSA.
• The PSA test has been widely used to screen men for prostate cancer. It is also used to monitor men who have been diagnosed with prostate cancer to see if their cancer has recurred (come back) after initial treatment or is responding to therapy.
• Some advisory groups now recommend against the use of the PSA test to screen for prostate cancer because the benefits, if any, are small and the harms can be substantial. None recommend its use without a detailed discussion of the pros and cons of using the test.”
http://www.cancer.gov/cancertopics/factsheet/detection/PSA
![Page 44: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/44.jpg)
Key Points – Prostate Cancer
• Prostate cancer is primarily a disease of older men.
• African-American men have up to twice the incidence and mortality of Caucasian men.
• The RNASEL gene is associated with hereditary forms of prostate cancer.
• Early onset may be asymptomatic, or associated with hematuria or dysuria; whereas bone pain is a common symptom of late onset.
• DRE detection of prostatic cancer is derived from the fact that 70% arise in the peripheral zone.
![Page 45: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/45.jpg)
Prostate Cancer Quiz
![Page 46: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/46.jpg)
Thank you
![Page 47: Prostate Pathophysiology Charles L. Hitchcock, MD PhD Associate Professor - Clinical Department of Pathology](https://reader035.vdocuments.us/reader035/viewer/2022062308/56649d195503460f949ee3ce/html5/thumbnails/47.jpg)
Survey
We would appreciate your feedback on this module. Click on the button below to complete a brief survey. Your responses and comments will be shared with the module’s author, the LSI EdTech team, and LSI curriculum leaders. We will use your feedback to improve future versions of the module.
The survey is both optional and anonymous and should take less than 5 minutes to complete.
Survey